Erasca–BMS Tests Unproven Pan-RAS Plus PRMT5 Combo in MTAP-Deleted PDAC
Clinical Trial Updates

Erasca–BMS Tests Unproven Pan-RAS Plus PRMT5 Combo in MTAP-Deleted PDAC

Published : 21 Nov 2026

The Overview
Erasca, Inc. announced a clinical trial collaboration and supply agreement (CTCSA) with Bristol Myers Squibb (BMS) to evaluate Erasca’s pan-RAS molecular glue, ERAS-0015, in combination with BMS’s investigational PRMT5 inhibitor, navlimetostat (BMS-986504). The Phase 1/2 study will investigate the combination in patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC). Under the agreement, BMS will sponsor the clinical trial, and Erasca will supply ERAS-0015, with both parties retaining development and commercial rights to their respective compounds on a mutually non-exclusive basis. This collaboration aims to leverage complementary mechanisms to address the challenges in MTAPdel PDAC and enhance antitumor activity.
Knolens Analysis

No closely comparable precedent exists for a pan-RAS molecular glue plus PRMT5 inhibitor in MTAP-deleted pancreatic ductal adenocarcinoma, and the collaboration is pre-clinical announcement only with no dose, response, progression-free survival, overall survival or safety disclosed. Rationale rests on single-component signals: pan-RAS inhibitor daraxonrasib doubled overall survival versus chemotherapy in previously treated metastatic PDAC in Phase 3, and BMS-986504 monotherapy produced a confirmed partial response in MTAP-deleted disease in a case-level NSCLC report, neither testing the combination in PDAC. [1] The bar is narrow: NAPOLI-3 in 770 patients showed 11.1 months versus 9.2 months (HR 0.83, 95% CI 0.70-0.99), NAPOLI-1 showed 6.1 months versus 4.2 months (HR 0.67), and POLO in 154 germline BRCA patients showed median PFS 7.4 months versus 3.8 months (HR 0.53) with no overall survival difference and grade ≥3 events 49% versus 25%. [2] Payer differentiation is already scored, with FOLFIRINOX at ESMO-MCBS v1.1 score 5 and gemcitabine-nab-paclitaxel and nanoliposomal irinotecan-5-FU-LV at score 3. BMS will sponsor the Phase 1/2 with non-exclusive rights retained, so advancement depends entirely on generating combination-specific tolerability and durable response data sufficient for a biomarker-restricted pathway. [3]

Planned Phase 1/2 with no efficacy or safety stated; supporting signals are daraxonrasib Phase 3 monotherapy and a single-patient BMS-986504 response in NSCLC. [1]

At a Glance
IndicationMTAP-deleted pancreatic ductal adenocarcinoma
DrugERAS-0015 and navlimetostat
Mechanism of Actionpan-RAS molecular glue and PRMT5 inhibitor
CompanyErasca, Inc.
Trial PhasePhase 1/2
CategoryClinical Trial Event
Sub CategoryTrial Initiation / First Patient In (FPI)
Therapeutic AreaOncology
Collaboration PartnerBristol Myers Squibb
Combination Partner Drugnavlimetostat (BMS-986504)
Combination Partner MOAPRMT5 inhibitor
Patient SubpopulationMTAP-deleted (MTAPdel)
Agreement TypeClinical Trial Collaboration and Supply Agreement (CTCSA)
Trial SponsorBristol Myers Squibb
Drug Supply (Erasca)ERAS-0015
Agreement RightsParties retain development and commercial rights, mutually non-exclusive
Press Release DateNovember 17, 2026
Previous Trial (ERAS-0015)AURORAS-1

Erasca and BMS Partner to Evaluate ERAS-0015 in Pancreatic Cancer

Erasca, Inc. announced a clinical trial collaboration and supply agreement (CTCSA) with Bristol Myers Squibb (BMS) to evaluate Erasca’s pan-RAS molecular glue, ERAS-0015, in combination with BMS’s investigational PRMT5 inhibitor, navlimetostat (BMS-986504). The Phase 1/2 study will investigate the combination in patients with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC). Under the agreement, BMS will sponsor the clinical trial, and Erasca will supply ERAS-0015, with both parties retaining development and commercial rights to their respective compounds on a mutually non-exclusive basis. This collaboration aims to leverage complementary mechanisms to address the challenges in MTAPdel PDAC and enhance antitumor activity.

  • The agreement establishes a mutually non-exclusive partnership where Bristol Myers Squibb will sponsor the Phase 1/2 clinical trial, and Erasca will supply ERAS-0015. Both companies will retain independent development and commercial rights to their respective compounds, fostering a collaborative yet independent approach to advancing the combination therapy.
  • The collaboration targets MTAP-deleted pancreatic ductal adenocarcinoma (PDAC), a patient population where nearly all tumors also harbor co-occurring RAS mutations. This genetic profile creates a unique dependency, suggesting that simultaneous inhibition of RAS and PRMT5 pathways with ERAS-0015 and navlimetostat, respectively, could significantly enhance antitumor activity and address current treatment challenges.
  • ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue. Early dose escalation data from the AURORAS-1 Phase 1 trial in RAS-mutant solid tumors demonstrated favorable safety and tolerability, linear pharmacokinetics, and confirmed/unconfirmed partial responses across various tumor types and RAS mutations, including confirmed responses at doses as low as 8 mg once daily.

Unpacking the Genetic Drivers of MTAP-Deleted PDAC

MTAP deletion in pancreatic cancer is defined by a canonical focal deletion event at 9p21.3. MTAP deletion was detected in 14 cases (2.4%, 95% confidence interval [CI], 1.45-4.02%), with Concurrent CDKN2A loss was observed in 92.9% of MTAP-deleted tumors, and 64.3% showed additional CDKN2B loss, indicating a coordinated focal deletion event at 9p21.3. Across the full cohort, deletion frequency peaked at the 9p21 locus, and among MTAP-deleted tumors, co-deletion frequency decreased with increasing genomic distance. In a nationwide genomic cohort, MTAP deletion was identified in 27.3% of pancreatic cancers, with high frequencies in pancreatic ductal adenocarcinoma (PDAC) (28.0%) and adenosquamous carcinoma (35.0%), while PDAC, ~22% of which are MTAP-del, was examined in preclinical models of the MTA-cooperative PRMT5 inhibitor BMS-986504.

The MTAP-deleted genomic context is shaped by co-occurring driver alterations and a stable genomic background. MTAP deletion strongly co-occurred with CDKN2A/2B deletion and was associated with major driver alterations (KRAS, TP53, SMAD4), while showing no association with high TMB or MSI. In pancreatic cancer, MTAP deletion was more common in KRAS-mutant tumors (19.8%) compared with KRAS wild-type tumors (8.9%). Across cancer types, MTAP deletion was less frequent in RB1-mutant tumors (pan-cancer: 3.2%, pancreatic: 7.6%) than in RB1 wild-type tumors (9.9%, 18.7%). All MTAP-deleted tumors were microsatellite stable and low tumor mutational burden (TMB-low).

At the molecular level, MTAP deletion defines a therapeutically actionable molecular subset of cancers due to synthetic lethal vulnerability to PRMT5 and MAT2A inhibition. Protein arginine methyltransferase 5 (PRMT5) is a synthetic lethal target in MTAP-deleted (MTAP-del) cancers, and PRMT5 inhibition disrupted RNA splicing of genes essential for PDAC growth. While PRMT5 and KRAS regulated distinct transcriptomes, they converged on pathways governing cancer cell growth and expression of PDAC-essential genes. PRMT5 directly bound to the promoter region of c-Myc and activated its transcription, while transcriptionally activated c-Myc in turn inhibited proteasome-mediated degradation of PRMT5 and enhanced its protein stability, resulting in increased PRMT5 expression. Compensatory spliceosomal reprogramming contributes to adaptation to PRMT5 inhibition, with PRMT5 inhibitors induce upregulation of RNA-binding proteins, including RNA-binding protein 39 (RBM39), and loss of several genes sensitized to PRMT5 inhibition, including members of the MAPK pathway.

Designing the ERAS-0015 + Navlimetostat Combination Trial

MTAP-deleted pancreatic ductal adenocarcinoma has been characterized through large genomic cohorts, preclinical combination models, and diagnostic biopsy studies. Designs range from nationwide sequencing of thousands of tumors to cell and xenograft experiments and CRISPR screens, with endpoints spanning survival, treatment response, and molecular readouts.

Study focus Design and population Endpoints and key data points
Nationwide genomic analysis in pancreatic cancer Retrospectively analyzed 8834 patients with pancreatic cancer profiled by FoundationOne® CDx; compared MTAP-deleted and non-deleted groups Clinicopathological characteristics, co-occurring genomic alterations, tumor mutational burden (TMB), microsatellite instability (MSI), overall survival (OS), and treatment response to first- and second-line chemotherapies; MTAP deletion in 27.3% of pancreatic cancers, 28.0% in pancreatic ductal adenocarcinoma (PDAC) and 35.0% in adenosquamous carcinoma; median OS 24.3 vs. 29.9 months; P < 0.0001; CDKN2A-deleted subcohort HR: 0.96; 95% CI: 0.85-1.08; objective response and disease control rates to gemcitabine plus nab-paclitaxel or FOLFIRINOX were comparable
BMS-986504 and KRAS inhibitors in MTAP-deleted KRAS-mutant PDAC Focused on PDAC, ~22% of which are MTAP-del; tested BMS-986504 in MTAP-del cells and xenograft models with CRISPR/Cas9 loss-of-function screens and RNA-sequencing Suppression of PRMT5 function and cell growth; enhanced and prolonged suppression of PDAC growth with concurrent inhibition of PRMT5 and KRASG12C/D; disruption of RNA splicing of genes essential for PDAC growth
MTAP loss in advanced gastrointestinal cancers Next-generation sequencing and comparative genomic and clinical analysis on 64 860 tumors comprising 5 GI cancers; retrospective comparison of MTAP-loss and MTAP-intact tumors Prevalence and genomic landscape and clinical outcomes; prevalence of MTAP-loss in GI cancers is 8.30%; most prevalent in PDAC at 21.7% and least in colorectal carcinoma (CRC) at 1.1%; 15% of IHCC, 8.7% of gastroesophageal adenocarcinoma, 2.4% of hepatocellular carcinoma; lower prevalence of microsatellite instability or elevated TMB in MTAP-loss PDAC, IHCC, and CRC
Chromosome 9p21 loss in adenosquamous carcinoma and PDAC Sequencing of 48 ASCP specimens and 98 PDAC tumour specimens to explore genomic landscape and prognostic biomarkers Homozygous deletion of 9p21.3 region (including CDKN2A, CDKN2B, and MTAP); higher frequency in ASCP (12.5% vs 2.0%, P = 0.022); disease-free survival mDFS = 4.17 vs 7.33 months, HR = 3.70, P = 0.009 in ASCP
CRISPR-drug screening with MTA-cooperative PRMT5 inhibitors Paralog and single gene targeting CRISPR library used to screen MTAP-deleted cancers in presence or absence of MTA-cooperative PRMT5 inhibitors; chemical inhibition in CDKN2A/MTAP-null, RAS-active tumors with in vivo testing Sensitization to PRMT5 inhibition including MAPK pathway members; synergy of KRAS, MEK, ERK, and RAF inhibitors with PRMT5 inhibition; complete responses in vivo with PRMT5 plus KRAS or RAF inhibitors
MTAP in small biopsy samples of pancreatic lesions Collected 27 EUS-FNAB of pancreatic masses; MTAP and S100P immunohistochemistry correlated with CDKN2A by fluorescence in-situ hybridization (FISH) and next-generation sequencing (NGS) Diagnostic accuracy; Approximately 25% of FNAB diagnosed as PDAC showed complete loss of MTAP expression; positive predictive value (100%), sensitivity (31.5%), specificity (100%); S100P positive in 71% of PDAC cases; panel including MTAP and S100P sensitivity (75%)

Exploring Other Combination Strategies in MTAP-Deleted PDAC

Recent studies in MTAP-deleted pancreatic ductal adenocarcinoma (PDAC) focus on MTA-cooperative PRMT5 inhibition as a backbone for combination therapy. Deletion of the MTAP gene defines a therapeutically actionable molecular subset due to synthetic lethal vulnerability to PRMT5 and MAT2A inhibition, with ~22% of PDAC reported as MTAP-del.

  • Concurrent PRMT5 and KRAS G12C/D inhibition: BMS-986504 suppressed PRMT5 function and cell growth in MTAP-del cells and xenograft models, and concurrent inhibition of PRMT5 and KRASG12C/D enhanced and prolonged suppression of PDAC growth. CRISPR/Cas9 loss-of-function screens implicated co-targeting KRAS as a combination strategy, with PRMT5 and KRAS converging on pathways governing cancer cell growth and expression of PDAC-essential genes.

  • MTA-cooperative PRMT5 inhibitors plus MAPK pathway inhibition: Chemical inhibition of MAPK pathway members using KRAS, MEK, ERK, and RAF inhibitors synergized with PRMT5 inhibition to kill CDKN2A/MTAP-null, RAS-active tumors. MTA-cooperative PRMT5 inhibitors combined with either KRAS or RAF inhibitors led to complete responses in vivo, and cell lines resistant to KRAS inhibition were not resistant to MTA-cooperative PRMT5 inhibitors and vice versa.

  • PRMT5 inhibition plus gemcitabine: Loss of PRMT5 activity synergistically enhances Gem cytotoxicity due to the accumulation of excessive DNA damage. Inhibition of PRMT5 results in RPA depletion and impaired homology-directed DNA repair (HDR) activity, creating conditional lethality and synergistic reduction of PDAC tumors in vivo.

  • PRMT5 inhibition plus RBM39 degradation: Combining PRMT5 inhibition with Indisulam-mediated RBM39 degradation yielded synergistic activity in cellular model systems. The combination significantly enhanced apoptotic cell death and suppressed tumor outgrowth in resistance assays compared to single-agent treatments, with concomitant suppression of DNA repair and metabolic pathways.

Frequently Asked Questions

What is the clinical significance of MTAP deletion in pancreatic ductal adenocarcinoma?
MTAP (Methylthioadenosine phosphorylase) deletion is a common genetic alteration in pancreatic ductal adenocarcinoma, often co-occurring with CDKN2A deletion. This deletion leads to an accumulation of methylthioadenosine (MTA), a substrate that can be exploited therapeutically. Identifying MTAP deletion helps stratify patients for targeted treatment approaches, particularly those involving PRMT5 inhibition. This genetic signature represents a potential vulnerability for therapeutic intervention.
How do therapeutic strategies target MTAP-deleted cancers?
Therapeutic strategies for MTAP-deleted cancers often leverage the synthetic lethality created by the absence of MTAP. This typically involves inhibiting PRMT5, an enzyme whose activity becomes critical for cell survival when MTAP is deleted. By blocking PRMT5, cancer cells accumulate toxic metabolites and undergo apoptosis, while healthy cells with intact MTAP are less affected. This selective targeting offers a promising avenue for precision oncology.
What is the role of PRMT5 inhibition in treating MTAP-deleted malignancies?
PRMT5 inhibition is a key therapeutic strategy for MTAP-deleted malignancies due to the synthetic lethality observed in these cells. In the absence of MTAP, cells accumulate methylthioadenosine (MTA), which is a natural inhibitor of PRMT5. However, MTAP-deleted cells become highly dependent on PRMT5 activity for survival, making them uniquely vulnerable to targeted PRMT5 inhibitors. This dependency provides a therapeutic window for selective cancer cell killing.
Why are combination therapies being explored for MTAP-deleted pancreatic cancer?
Combination therapies are being explored for MTAP-deleted pancreatic cancer to enhance efficacy and overcome potential resistance mechanisms. While single-agent PRMT5 inhibition shows promise, combining it with other targeted agents or chemotherapy may lead to more durable responses. These synergistic approaches aim to hit multiple vulnerabilities within the cancer cell, improving patient outcomes and potentially broadening the therapeutic index. This strategy seeks to maximize tumor regression and prevent disease progression.

References

  1. [1] Han M, Lee E et al.. Real-World Prevalence and Structural Validation of the Canonical 9p21 MTAP-CDKN2A/B Deletion in Non-NSCLC Solid Tumors. Cancers. 2026 Mar 10. 41899498
  2. [2] Hsu TW, Su CM et al.. Adenylosuccinate lyase in pancreatic ductal adenocarcinoma chemoresistance: from purine metabolism to metabolic vulnerability. Cancer drug resistance (Alhambra, Calif.). 2026. 42729694
  3. [3] Liu J, Hou X et al.. KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy. Gut. 2026 May 12. 41513443
  4. [4] Lyu SI, Knipper K et al.. MTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy. Scientific reports. 2026 May 13. 42129334
  5. [5] Bhandari K, Aravindan S et al.. Nuclear Symmetric Dimethylarginine Staining is Indicative of Pancreatic Ductal Adenocarcinoma. Pancreas. 2025 Sep 3. 40892381
  6. [6] Jiang Y, Wu Y et al.. Loss of chromosome 9p21 is associated with a poor prognosis in adenosquamous carcinoma of the pancreas. Precision clinical medicine. 2023 Dec. 38024139
  7. [7] Drizyte-Miller K, Engstrom LD et al.. Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer. Cancer research. 2025 Sep 15. 40694535
  8. [8] Yu S, Doyle LA et al.. The diagnostic utility of methylthioadenosine phosphorylase immunohistochemistry for pancreatic ductal adenocarcinoma in FNA and small biopsy specimens. Cancer cytopathology. 2024 Feb. 38054349
  9. [9] Neel NF, Rossman KL et al.. The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector. Molecular and cellular biology. 2012 Apr. 22331470
  10. [10] Ngodup T, Elson B et al.. A stromal PAI1-tPA axis orchestrates immunosuppression in pancreatic cancer. Science advances. 2026 Apr 3. 41931610
  11. [11] Gironi LC, Zottarelli F et al.. Dermatologic surveillance in healthy carriers of CDKN2A and p.E318K MITF germline variants from melanoma-prone families: a 14 years hospital-based experience. Melanoma research. 2025 Dec 1. 40623218
  12. [12] Mei W, Ding Y et al.. The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. Journal of advanced research. 2026 Aug. 41203070
  13. [13] Knoll N, Masser S et al.. CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. Cancer research. 2025 Sep 15. 40694540
  14. [14] Lee MKC, Grimmond SM et al.. PRMT5: An Emerging Target for Pancreatic Adenocarcinoma. Cancers. 2021 Oct 13. 34680285
  15. [15] Scales MK, Velez-Delgado A et al.. Combinatorial Gli activity directs immune infiltration and tumor growth in pancreatic cancer. PLoS genetics. 2022 Jul. 35867772
  16. [16] Deipenbrock A, Hofer L et al.. Targeting stroma-mediated T-cell exclusion and functional exhaustion in pancreatic ductal adenocarcinoma through CXCR4 and PD-1 blockade. Frontiers in immunology. 2026. 42553398
  17. [17] Ikushima H, Watanabe K et al.. Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data. ESMO open. 2025 Apr. 40138743
  18. [18] Fivaz M, Bornand A et al.. Actionable mutations in pancreatic cancer: where targeted therapies are making a difference. BMJ open gastroenterology. 2025 Nov 27. 41309265
  19. [19] Meric-Bernstam F, Gutierrez M et al.. Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors. Cancer research communications. 2025 Sep 1. 40762544
  20. [20] Martin TD, Der CJ. Differential involvement of RalA and RalB in colorectal cancer. Small GTPases. 2012 Apr-Jun. 22790202

Contact Us

📍

Address

350 Springfield Avenue,
Suite #200 Summit, NJ 07901

✉️

For General Inquiry

info@pienomial.com

Related Posts